GenSpera Receives Patent on Second Prostate-Targeting Oncology Drug

SAN ANTONIO--(BUSINESS WIRE)--GenSpera, Inc. (OTC.BB: GNSZ) announced that its patent application, entitled "Activation of Peptide Prodrugs by HK2," has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,906,477. The patent covers the composition of Ac-GKAFRR-L12ADT, a prodrug that is cleaved specifically by HK2, an enzyme secreted by prostate cancer cells, to deliver a potent thapsigargin derivative selectively to prostate cancers. Thapsigargin is the active ingredient in the GenSpera prodrug platform. Ac-GKAFRR-L12ADT is GenSpera's second drug that specifically targets prostate cancer.

"The issuance of this patent further strengthens our intellectual property position for Ac-GKAFRR-L12ADT and affords recognition of its novel utility in prostate cancer," commented Craig Dionne, Ph.D., GenSpera CEO and President. "This exciting drug is positioned in our development pipeline behind G-202 for all solid tumors, and G-115 for prostate cancer. It is important that we continue to expand and defend our thapsigargin prodrug research and development into areas of high unmet medical needs and commercial opportunities."

The described invention features a prodrug that is selectively activated within prostate tumors by an enzyme, Human Kallikrein-2 (HK2), found within prostate tissue and prostate cancer tumors. In preclinical testing, this drug was shown to dramatically inhibit the growth of tumors in animal models of human prostate cancer. GenSpera, Inc. owns and controls all rights to Ac-GKAFRR-L12ADT and anticipates a strategic partnership to maximize the value of the drug as it progresses through future clinical trials.

About GenSpera

GenSpera, Inc., is a development stage oncology company focused on therapeutics that deliver a potent, unique and patented drug directly to tumors. GenSpera's technology platform combines a potent, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that releases the drug only within the tumor. Unlike standard cancer drugs, thapsigargin kills cells independent of their division rate, thus making it effective at killing all fast- and slow-growing cancers and cancer stem cells. GenSpera's prodrug platform is the subject of nine issued patents, with four additional patents pending.

GenSpera is conducting a Phase I clinical trial targeting solid tumor cancers with its lead drug, G-202, at Johns Hopkins University, the University of Wisconsin and the Cancer Therapy and Research Center in San Antonio. The Company anticipates completion of its Phase I trial in Q2 2011. Upon successful completion of its Phase I trial, GenSpera expects to initiate multiple Phase II trials for G-202 in several different types of cancer. The company's pipeline of drugs also includes G-115 and Ac-GKAFRR-L12ADT that both directly target prostate cancer.

GenSpera, Inc. owns and controls all rights to G-202, G-115, and Ac-GKAFRR-L12ADT and anticipates a strategic partnership to maximize the value of these drugs as they progress through future clinical trials.

For more information, please visit the Company's website: www.genspera.com.

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.